Hansen Iben Onsberg, Sørensen Anders Lindholm, Hasselbalch Hans Carl
Department of Haematology, Copenhagen University Hospital Roskilde, Copenhagen, Denmark.
Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Eur J Haematol. 2017 Jan;98(1):75-84. doi: 10.1111/ejh.12787. Epub 2016 Sep 4.
In an era of controversy in regard to 'hydroxyurea-leukaemogenicity' and when interferon-alfa2 (IFN) is being revived in the treatment of Philadelphia-negative myeloproliferative neoplasms (MPNs), we aim in this single-centre observational study to describe the frequencies of second malignancies in a cohort of MPN patients treated with hydroxyurea (HU) or IFN monotherapy or the combination of these agents.
Records of a MPN cohort of 196 patients were reviewed, and a retrospective analysis was performed on 90 patients treated with HU, 38 patients treated with IFN and 68 patients treated with both IFN and HU. Logistic regression was used to compare frequencies in second malignancies.
Patients treated with HU had a significantly higher risk of developing all second malignancies compared with patients treated with IFN [HU vs. IFN: OR of 4.01 (95%CI: 1.12-14.27, P-value: 0.023) and HU-IFN vs. IFN: OR 5.58 (95%CI: 1.55-20.15, P-value: 0.004)].
We have found an increased risk of second malignancies in MPN patients treated with HU compared with patients treated with IFN.
在关于“羟基脲致白血病性”存在争议的时代，以及干扰素-α2（IFN）在费城阴性骨髓增殖性肿瘤（MPN）治疗中再度兴起之际，我们在这项单中心观察性研究中旨在描述接受羟基脲（HU）或IFN单药治疗或这两种药物联合治疗的MPN患者队列中第二原发性恶性肿瘤的发生频率。
回顾了一个196例MPN患者队列的记录，并对90例接受HU治疗的患者、38例接受IFN治疗的患者和68例接受IFN与HU联合治疗的患者进行了回顾性分析。采用逻辑回归比较第二原发性恶性肿瘤的发生频率。
与接受IFN治疗的患者相比，接受HU治疗的患者发生所有第二原发性恶性肿瘤的风险显著更高[HU与IFN相比：比值比为4.01（95%置信区间：1.12 - 14.27，P值：0.023），HU - IFN与IFN相比：比值比为5.58（95%置信区间：1.55 - 20.15，P值：0.004）]。
我们发现，与接受IFN治疗的MPN患者相比，接受HU治疗的患者发生第二原发性恶性肿瘤的风险增加。
